Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized. Novel compounds (3-9) have been designed using a conjunctive approach that combines the benzylpiperidine moiety of the AChE inhibitor donepezil (1) and the indolyl propargylamino moiety of the MAO inhibitor N-[(5-benzyloxy-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine (2), connected through an oligomethylene linker. The most promising hybrid (5) is a potent inhibitor of both MAO-A (IC50=5.2±1.1 nM) and MAO-B (IC50=43±8.0 nM) and is a moderately potent inhibitor of AChE (IC50=0.35±0.01 μM) and BuChE (IC50=0.46±0.06 μM). Moreover, molecular modeling and kinetic studies support the dual binding site to AChE, which explains the inhibitory effect exerted on Aβ aggregation. Overall, the results suggest that the new compounds are promising multitarget drug candidates with potential impact for Alzheimer's disease therapy.

[1]  A. Cavalli,et al.  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. , 2008, Journal of medicinal chemistry.

[2]  Ana Martínez,et al.  Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. , 2006, Current pharmaceutical design.

[3]  R. Neve,et al.  Tissue Distribution of Human Monoamine Oxidase A and B mRNA , 1990, Journal of neurochemistry.

[4]  M. Garcia-Alloza,et al.  Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease , 2005, Neuropsychologia.

[5]  H. Nakano.  [Monoamine oxidase]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[6]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[7]  J. Lehmann,et al.  Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. , 2008, Journal of medicinal chemistry.

[8]  V. Andrisano,et al.  Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action. , 2009, Bioorganic & medicinal chemistry letters.

[9]  Maurizio Recanatini,et al.  A small molecule targeting the multifactorial nature of Alzheimer's disease. , 2007, Angewandte Chemie.

[10]  Andrea Mattevi,et al.  Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Jacobsen,et al.  Alzheimer's disease: from pathology to therapeutic approaches. , 2009, Angewandte Chemie.

[12]  A. Spek,et al.  Synthesis and Structure-Activity Relationships of Conformationally Constrained Histamine H3 Receptor Agonists. , 2003 .

[13]  S. David Morley,et al.  Validation of an empirical RNA-ligand scoring function for fast flexible docking using RiboDock® , 2004, J. Comput. Aided Mol. Des..

[14]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[15]  D. Muñoz-Torrero.  Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. , 2008, Current medicinal chemistry.

[16]  J Andrew McCammon,et al.  Optimized Radii for Poisson-Boltzmann Calculations with the AMBER Force Field. , 2005, Journal of chemical theory and computation.

[17]  Wei Huang,et al.  Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[18]  A. Parini,et al.  Reactive oxygen species production by monoamine oxidases in intact cells , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[19]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[20]  M. Cruces.  Dérivés acétyléniques et alléniques de la 2-(5-méthoxy-indolyl) méthylamine: synthèse et évaluation comme inhibiteurs sélectifs des monoamines oxydases A et B , 1990 .

[21]  E. Perry,et al.  CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.

[22]  M. Youdim,et al.  A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo‐APP translation and processing , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  A. Cavalli,et al.  Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. , 2003, Journal of medicinal chemistry.

[24]  J. P. Johnston.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue. , 1968, Biochemical pharmacology.

[25]  T. Aoki,et al.  Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419. , 2005, Bioorganic & medicinal chemistry.

[26]  J. Grosche,et al.  A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques. , 2009, Organic & biomolecular chemistry.

[27]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[28]  U. Kristiansen,et al.  Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol. , 1995, Journal of medicinal chemistry.

[29]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[30]  P. Riederer,et al.  Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl , 1986, Journal of neurochemistry.

[31]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[32]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[33]  K. Tipton,et al.  Determination of monoamine oxidase concentrations in rat liver by inhibitor binding. , 1986, Biochemical pharmacology.

[34]  I Silman,et al.  A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. , 2001, Biochemistry.

[35]  Yuan-Ping Pang,et al.  Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. , 2006, Journal of medicinal chemistry.

[36]  R. Terry,et al.  ULTRASTRUCTURAL STUDIES IN ALZHEIMER'S PRESENILE DEMENTIA. , 1964, The American journal of pathology.

[37]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[38]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[39]  W. Burke,et al.  Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. , 2001, Free radical biology & medicine.

[40]  M. Unzeta,et al.  Relevance of benzyloxy group in 2‐indolyl methylamines in the selective MAO‐B inhibition , 1999, British journal of pharmacology.

[41]  M. Youdim,et al.  Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate] , 2001, Cellular and Molecular Neurobiology.

[42]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[43]  J. Olin,et al.  Galantamine for Alzheimer's disease. , 2004, The Cochrane database of systematic reviews.

[44]  Wolfgang Sippl,et al.  Design, Synthesis, and Structure—Activity Relationships of a Series of 3‐[2‐(1‐Benzylpiperidin‐4‐yl)ethylamino]pyridazine Derivatives as Acetylcholinesterase Inhibitors. , 2001 .

[45]  R J Harvey,et al.  Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[46]  F. J. Luque,et al.  Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. , 2009, Journal of medicinal chemistry.

[47]  X. Barril,et al.  Virtual screening in structure-based drug discovery. , 2004, Mini reviews in medicinal chemistry.

[48]  S. Mandel,et al.  Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. , 2010, Journal of Alzheimer's Disease.

[49]  E. Yamashita,et al.  Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors , 2008, Proceedings of the National Academy of Sciences.

[50]  G. O'malley,et al.  Imino 1,2,3,4-tetrahydrocyclopent[b]indole carbamates as dual inhibitors of acetylcholinesterase and monoamine oxidase , 1996 .

[51]  H. Dringenberg,et al.  Alzheimer's disease: more than a ‘cholinergic disorder' — evidence that cholinergic–monoaminergic interactions contribute to EEG slowing and dementia , 2000, Behavioural Brain Research.

[52]  C. Lanni,et al.  Acetylcholinesterase inhibitors: novel activities of old molecules. , 2004, Pharmacological research.

[53]  M. Tsolaki,et al.  Rivastigmine for Alzheimer's disease. , 2000, The Cochrane database of systematic reviews.

[54]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[55]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[57]  E. Fernández‐Álvarez,et al.  The kinetics of monoamine oxidase inhibition by three 2-indolylmethylamine derivatives. , 1990, Biochemical Pharmacology.

[58]  P. Riederer,et al.  Monoamine oxidase-B inhibition in Alzheimer's disease. , 2004, Neurotoxicology.

[59]  Jerry J Buccafusco,et al.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.

[60]  Andrea Mattevi,et al.  Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. , 2005, Journal of medicinal chemistry.

[61]  K. Tipton,et al.  Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. , 1981, Biochemical pharmacology.

[62]  F. J. Luque,et al.  3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. , 2002, Biochemistry.

[63]  Zoran Radić,et al.  Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Youdim,et al.  Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. , 2010, ACS chemical biology.

[65]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[66]  M. Youdim,et al.  Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil , 2006, Neurotoxicity Research.

[67]  Andrea Mattevi,et al.  Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. , 2004, Journal of medicinal chemistry.

[68]  Maurizio Recanatini,et al.  Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. , 2007, Journal of medicinal chemistry.

[69]  C. Pérez,et al.  Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. , 2005, Bioorganic & medicinal chemistry.

[70]  Xiaoxiang Zhu,et al.  A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase , 2001, Current medical research and opinion.

[71]  N. Durany,et al.  Oxidative stress in Alzheimer disease , 2009, Cell adhesion & migration.

[72]  O. Lockridge,et al.  Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase. , 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

[73]  S. Brimijoin,et al.  Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. , 2005, Current Alzheimer research.

[74]  C. Jang,et al.  Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors. , 2011, Journal of medicinal chemistry.

[75]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[76]  Christina A. Wilson,et al.  Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets , 2008, Behavioural Brain Research.

[77]  L. Pardo,et al.  Molecular determinants of MAO selectivity in a series of indolylmethylamine derivatives: biological activities, 3D-QSAR/CoMFA analysis, and computational simulation of ligand recognition. , 2000, Journal of medicinal chemistry.

[78]  Filippo Caraci,et al.  Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. , 2010, European journal of pharmacology.

[79]  N. Inestrosa,et al.  Amyloid-β-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease , 2010, Molecular Neurodegeneration.

[80]  M. Youdim,et al.  Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. , 2009, Journal of medicinal chemistry.

[81]  José Marco-Contelles,et al.  Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. , 2006, Journal of medicinal chemistry.

[82]  Peter V Coveney,et al.  Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases. , 2008, Journal of the American Chemical Society.

[83]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[84]  P. Carrupt,et al.  Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. , 2001, Journal of medicinal chemistry.

[85]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[86]  Cheng Luo,et al.  Structural optimization and biological evaluation of substituted bisphenol A derivatives as beta-amyloid peptide aggregation inhibitors. , 2010, Journal of medicinal chemistry.

[87]  V. Talesa.  Acetylcholinesterase in Alzheimer's disease , 2001, Mechanisms of Ageing and Development.

[88]  M. Froment,et al.  Aging of cholinesterases phosphylated by tabun proceeds through O-dealkylation. , 2008, Journal of the American Chemical Society.

[89]  A. Bidon-Chanal,et al.  Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents. , 2010, Current pharmaceutical design.

[90]  F. J. Luque,et al.  Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. , 2005, Journal of medicinal chemistry.